Who are Placebo to sitagliptin plus metformin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pioglitazone + Alogliptin, Linagliptin / Metformin Oral Tablet, Metformin plus vildagliptin, sitagliptin and acarbose, Metformin and Saxagliptin, Sitagliptin combined with metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-sitagliptin-plus-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo to sitagliptin plus metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to sitagliptin plus metformin (Placebo to sitagliptin plus metformin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor and biguanide. Area: Diabetes.

phase 3 DPP-4 inhibitor and biguanide DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to sitagliptin plus metformin (Placebo to sitagliptin plus metformin) — Merck Sharp & Dohme LLC. Sitagliptin plus metformin works by inhibiting dipeptidyl peptidase-4 (DPP-4) and reducing glucose production in the liver, and increasing insulin secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to sitagliptin plus metformin TARGET	Placebo to sitagliptin plus metformin	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide	DPP-4
Pioglitazone + Alogliptin	Pioglitazone + Alogliptin	Celltrion Pharm, Inc.	marketed	Thiazolidinedione + DPP-4 inhibitor combination	PPAR-γ and DPP-4
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
Metformin plus vildagliptin	Metformin plus vildagliptin	Sheba Medical Center	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
Metformin and Saxagliptin	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor and biguanide class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to sitagliptin plus metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-sitagliptin-plus-metformin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab